Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation and Depletion (2021 - 2025)

Krystal Biotech's Depreciation and Depletion history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 12.51% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.7 million, down 3.29%, while the annual FY2025 figure was $5.7 million, 4.47% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $1.5 million at Krystal Biotech, up from $1.4 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.8 million in Q2 2024 and bottomed at $412000.0 in Q4 2021.
  • The 5-year median for Depreciation and Depletion is $1.2 million (2023), against an average of $1.1 million.
  • The largest annual shift saw Depreciation and Depletion soared 152.63% in 2023 before it fell 25.06% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $412000.0 in 2021, then surged by 147.09% to $1.0 million in 2022, then soared by 43.32% to $1.5 million in 2023, then decreased by 6.31% to $1.4 million in 2024, then grew by 12.51% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Depreciation and Depletion are $1.5 million (Q4 2025), $1.4 million (Q3 2025), and $1.3 million (Q2 2025).